Importantly, significantly greater tumor growth inhibition from 212Pb-225.28 (0.30 MBq) was observed relative to a slightly higher dose of 212Pb-F3-C25 (0.33 MBq), demonstrating the efficacy and specificity of the CSPG4-targeted RIC against an in vivo model of human TNBC. Here, CSPG4 is linked to neoplasm.